AbCellera, which is developing a treatment for COVID-19, has announced clinical testing for its antibody drug could start as soon as July, CTV News reported.
The company has isolated around 500 antibodies that are candidates for new therapeutics to treat or prevent infections.
CEO Carl Hansen said the antibodies were identified in a single blood sample from one of the first COVID-19 patients in North America.
Last month, Canadian Prime Minster Justin Trudeau said that AbCellera would be among several Canadian companies receiving $192 million in federal funding for vaccine and treatment research.
To read more NewsPoints articles, click here.